|
|
||||||||
deficiency results in reduced NF-
B levels
in pregnant mice
1 Division of Infectious Diseases and 2 Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262
| |
ABSTRACT |
|---|
|
|
|---|
Interleukin (IL)-1
-deficient
(IL-1
/
) mice
were assessed for cytokine production during pregnancy. A significant
reduction in nuclear factor (NF)-
B p65 protein content was observed
in the uteri and spleens of pregnant
IL-1
/
mice, as
demonstrated by immunohistochemistry and Western immunoblot analysis.
In addition, electromobility gel shift assay revealed less DNA binding
activity of NF-
B p65-containing complex in pregnant IL-1
/
mice. To
investigate differences in cytokine production regulated by NF-
B,
the levels of tumor necrosis factor-
, macrophage inflammatory protein-1
, and interferon-
were measured in the uterine wall, spleen homogenates, and spleen cell cultures obtained from pregnant mice. Endocervical administration of lipopolysaccharide (LPS) increased
cytokine levels in both wild-type
(IL-1
+/+) and
IL-1
/
animals,
but in IL-1
/
mice
this response was 50-75% lower. Splenocytes from nonpregnant mice
exhibited decreased LPS-induced cytokine production when primed in
vitro with progesterone. This suppression was 25% greater in
IL-1
/
than in
IL-1
+/+ mice. These data
suggest that constitutive NF-
B p65 protein synthesis is regulated by
IL-1
, particularly during pregnancy.
p65 nuclear factor-
B; lipopolysaccharide; inflammation
| |
INTRODUCTION |
|---|
|
|
|---|
INTERLEUKIN (IL)-1 is a multifunctional cytokine, which
induces several genes associated with inflammation, infection, and tissue injury (reviewed in Ref. 14). IL-1 stimulates the synthesis of
other proinflammatory cytokines, including tumor necrosis factor (TNF)-
, IL-6, and chemokines (23, 30, 34, 38, 43). Surprisingly, in
response to systemic administration of lipopolysaccharide (LPS),
IL-1
-deficient
(IL-1
/
) mice do
not exhibit altered circulating levels of TNF-
or IL-6 (18). In
addition, no differences between wild-type
(IL-1
+/+) and
IL-1
/
mice in
LPS-induced toxicity have been observed (16). The only difference
reported to date is the failure of
IL-1
/
mice to
increase leptin mRNA in fat tissue and to elevate leptin levels in the
circulation after systemic LPS administration (15).
We have recently reported that late in pregnancy
IL-1
/
mice
exhibit reduced levels of uterine TNF-
, macrophage inflammatory protein-1
(MIP-1
), and IL-6 in response to endocervical injection of LPS compared with IL-1
+/+
mice (37). However, the mechanism for this reduction remains unknown.
IL-1
is a potent activator of nuclear factor (NF)-
B nuclear
translocation, and NF-
B and Ap-1 binding motifs are functional in
the IL-1
promoter (1, 9, 19, 20, 27). Therefore IL-1
and NF-
B
are linked by a positive feedback loop serving to amplify inflammatory
signals (21). Furthermore, both IL-1
and IL-1
have been reported
to increase steady-state levels of NF-
B2 (p52) transcript and
protein (25). In pregnancy, the uterine levels of IL-1 increase as
parturition approaches (12). However, despite this increase, responses
mediated by NF-
B are relatively suppressed due to the negative
interaction between the NF-
B p65 subunit and progesterone (24, 44,
47). NF-
B, and particularly the p65 subunit, is required for the
transcription and production of TNF-
, IL-6, and MIP-1
(42, 44,
48, 49). Therefore the altered activation of NF-
B may be responsible
for reduction in cytokine production (37).
We hypothesized that IL-1
deficiency associated with a
pregnancy-related endocrine environment may lead to an alteration of
NF-
B-mediated cytokine production in response to LPS. In the present study, differences in NF-
B p65 subunit protein content and nuclear translocation in pregnant
IL-1
/
and
pregnant IL-1
+/+ mice
challenged with LPS were examined.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals.
IL-1
/
and
IL-1
+/+ mice of mixed C57BL/6
and 129Sv(ev) background were obtained from Dr. H. Zheng (Merck,
Rahway, NJ) (50) and bred in the University of Colorado Health Sciences
Center animal facility. Mating (using one male per three females) was verified by the presence of a vaginal plug. All mice were allowed free
access to food and water and exposed to 12:12-h light-dark cycles
before and after experimentation was initiated.
Chemicals, reagents, and instruments.
Antibodies to NF-
B were raised in rabbits against the carboxy
terminus of the human p65 or p50 subunit of NF-
B (Santa Cruz Biotechnology, Santa Cruz, CA). Both antibodies cross-react with the
mouse NF-
B subunits. The enhanced chemiluminescence kit was obtained
from Amersham (Arlington Heights, IL). RPMI and penicillin-streptomycin sterile solutions were purchased from Cellgro (Waukesha, WI); fetal
bovine serum was from Life Technologies (Pascagoula, MS). Lyophilized
LPS (a phenol-extracted preparation from Escherichia coli 055:B5) as well as other chemicals including
water-soluble progesterone was purchased from Sigma Chemical (St.
Louis, MO). The endoscope (arthroscope; angle 0°; diameter 1.7 mm;
length 90 mm) was obtained from Comeg Endoscopy (Aurora, CO).
Experimental protocol.
Animal experimental studies were approved by the Animal Use and Care
Committee of the University of Colorado Health Sciences Center. On
day 14 or
15 of pregnancy (approximately 70%
gestation), both IL-1
+/+ and
IL-1
/
mice were
subjected to inhalation anesthesia with methoxyflurane (Metofane;
Mallinckrodt Veterinary, Mundelein, IL) using an inhalation chamber and
subsequent nasal anesthetic cone. Mice were placed in a dorsal supine
position and restrained with paper tape. After the perineal area was
washed with 70% isopropanol, the endoscope was inserted approximately
6-8 mm into the vagina until the cervix was visualized. A needle,
attached to the syringe and bent to an angle of 30°, was guided
through the vagina and visually advanced 3 mm into the cervix and 100 µl of LPS in saline (5 mg/kg) or corresponding amounts of sterile
saline were injected intracervically. This dose of LPS is not lethal
but required for cytokine response in C57BL mice injected
intraperitoneally (18). Both
IL-1
+/+ and
IL-1
/
pregnant
and nonpregnant mice were injected intracervically. Nonpregnant and
nonchallenged mice were included in this study for comparison. Animals
were killed by cervical dislocation 24 h after injection. Gestational
tissue and spleen specimens were collected. Uterine tissue (myometrium
and decidua) was separated from placenta. The spleen was dissected from
surrounding fat and fascia. Specimens were weighed and snap frozen in
liquid nitrogen or directly embedded in tissue freezing medium
(Triangle Biomedical Sciences, Durham, NC), frozen using dry ice-cold
2-methylbutane, and then stored at
70°C before use as will
be described.
NF-
B staining of uterine tissue.
Transverse 5-mm cryosections were prepared with a cryostat (IEC
Minotome Plus, Needham Heights, MA) and collected on
poly-L-lysine-coated slides
(Becton Dickinson, Franklin Lakes, NJ). Sections were fixed with a 70%
methanol-30% acetone solution for 10 min at
20°C. Slides
were washed three times with PBS for 5 min each, blocked in 10% normal
goat serum for 25 min at room temperature, and then incubated for 1 h
with rabbit polyclonal anti-NF-
B p65 antibody [Santa Cruz
Biotechnology; 1:40 dilution with PBS containing 1% bovine serum
albumin (BSA)]. After three washes with PBS, sections were
incubated for 45 min with Cy3-labeled goat anti-rabbit IgG (Jackson
Immuno Research Laboratories, West Grove, PA; 1:250 dilution with
PBS-1% BSA), then washed three times with PBS, and counterstained with
2.5 mg/ml bis-benzimide (Sigma) for nuclear staining and 5 µg/ml
fluorescein-labeled wheat-germ agglutinin (Molecular Probes, Eugene,
OR) for cell surface staining. Sections were then mounted with aqueous
antiquenching medium. To assess the specificity of immunostaining,
adjacent sections were incubated with nonimmune rabbit IgG (5 µg/ml
in PBS containing 1% BSA) as the replacement of the primary antibody
and then processed identically. All sections were stained at the same
time using the same antibody preparation. Images were observed at the
same confocal conditions and photographed using a Leica DMRXA confocal microscope.
Macrophage staining of uterine tissue. Rat anti-mouse macrophage F4/80 antigen monoclonal antibody (Caltag Laboratories, Burlingame, CA) at 10 µg/ml was used as the primary antibody for macrophage labeling (7), and Cy3-labeled goat anti-rat IgG (Jackson Immuno Research Laboratories; 1:125 dilution with PBS-1% BSA) was used as secondary antibody. The samples were stained as previously described.
Isolation and culture of spleen cells.
After aseptic removal of spleens, cell suspensions in RPMI with 10%
fetal bovine serum were prepared as previously described (11). Spleen
cells were cultured in 1.0 ml at 5 × 106 cells/ml in 24-well,
flat-bottom culture plates (Becton Dickinson) in the presence or
absence of LPS (10 µg/ml). Cultures were incubated at 37°C in a
humidified 5% CO2 atmosphere. In
some experiments, cells were preincubated with progesterone
(50-200 ng/ml) for 4 h before LPS treatment. Cultures incubated
for 24 h were subjected to three freeze-thaw cycles at
70°C.
Samples were then centrifuged for 10 min at 10,000 g, and cytokines were measured in the supernatants.
Tissue cytokine extraction. Tissue extracts were obtained using a modified method of Nishiyama et al. (36). Briefly, tissue samples were homogenized using Tissue Tearor 985-370 (Biospec Products) at 30,000 in 10 volumes of 0.1% Tween 20 in 0.01 M PBS (pH 7.4) for 1 min on ice. After centrifugation at 13,000 g for 15 min at 4°C, supernatants were assayed for cytokine levels.
Cytokine assays.
Concentrations of TNF-
and MIP-1
in tissue extracts or cell
culture medium were measured by liquid-phase electrochemiluminescence method (17) with a lower limit of detection of 10 pg/ml for MIP-1
and 60 pg/ml for TNF-
. Interferon-
was measured using ELISA kits
specific for murine cytokines (Endogen, Woburn, MA) with lower limit of
detection of 10 pg/ml. Cytokine levels were normalized by weight of
fresh tissue before homogenization.
Western immunoblotting.
Tissue was homogenized, as previously explained, in five volumes of
buffer containing (in mM) 25 Tris · HCl, 2 EDTA, and
1 phenylmethanesulfonyl fluoride, pH 7.4. After centrifugation at 4°C at 13,000 g for 15 min, the
supernatants were collected. Protein concentration was measured by
Coomassie Plus Protein Assay (Pierce, Rockford, IL) using BSA as the
standard. Samples, containing 20 µg of protein, were mixed 1:1 with
sample-prep buffer (Bio-Rad, Richmond, CA) and boiled for 5 min.
Electrophoresis was performed on 4-20% linear gradient
SDS-polyacrylamide gels (Bio-Rad, Hercules, CA). After electrophoretic
transfer to nitrocellulose membrane (Bio-Rad), membranes were stained
with Ponceau S (Sigma) to confirm the equal amount of protein between
samples, then washed and blocked for 1 h with PBS containing 0.1%
Tween 20 and 5% nonfat dried milk (antibody buffer), and then
incubated for 1.5 h at room temperature with rabbit polyclonal
anti-NF-
B p65 antibody (1:200 dilution with antibody buffer; Santa
Cruz Biotechnology). After sequential washing in 0.1% Tween 20 in PBS,
membranes were incubated at room temperature for 1 h with horseradish
peroxidase-linked goat anti-rabbit secondary antibody (Santa Cruz
Biotechnology; 1:5,000 dilution with antibody buffer) and detected
using the enhanced chemiluminescence system. Quantification of the
immunoblot was performed by computer-assisted densitometry (software
available from National Institutes of Health Application 1.599b4).
Detection of NF-
B by electrophoretic mobility shift
assay.
Snap-frozen tissues (approximately 100 mg for uterus or 10 mg for
spleen) were thawed at 4°C and washed with ice-cold PBS before
homogenization in 500 µl lysis buffer containing 10 mM HEPES (pH
7.9), 10 mM KCl, 1 mM EGTA, 1 mM DTT, and one tablet of Complete
Protease Inhibitor (Boehringer Mannheim, Indianapolis, IN). Nuclear
proteins were then extracted as previously described (41). Briefly,
homogenized tissue was incubated for 15 min on ice, and NP-40 (Sigma)
was added to a final concentration of 0.5% followed by vortexing for
10 s. Samples were centrifuged at 8,000 g for 15 min at 4°C and the
nuclear pellet was resuspended in 50 µl of nuclear extraction buffer
[20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EGTA, 1 mM DTT, and one
tablet of Complete Protease Inhibitor] and incubated on ice for
30 min with gentle vortexing every 10 min. The nuclear extract was then
clarified by centrifugation at 12,000 g for 5 min at 4°C. The
supernatants containing the nuclear proteins were quantified with the
Coomassie Plus protein assay (Pierce).
B consensus oligonucleotide
(AGTTGA
- CCCAGGC, binding site underlined,
Promega, Madison, WI) was 5' end-labeled with
[
-32P]ATP (NEN,
Boston, MA) using T4 polynucleotide kinase. Unincorporated nucleotide
was separated using a NucTrap Probe purification column (Stratagene, La
Jolla, CA). Ten micrograms of nuclear protein were incubated with
labeled oligonucleotide (150,000 counts/min) in binding buffer
[10 mM Tris · HCl (pH 7.5), 50 mM NaCl, 0.5 mM
EDTA, 1 mM MgCl2, 0.5 mg
poly(dI-dC), 1% NP-40, and 4% glycerol] for 25 min at room
temperature in a final volume of 25 µl. Subsequently, the products
were separated by electrophoresis on a 4% polyacrylamide-0.5 times
Tris-Borate-EDTA gel. The gel was then dried onto Whatman paper and exposed to an X-ray film overnight at
70°C with an intensifying screen.
For supershift studies, 1 µg of antibody to either p50 or p65 (Santa
Cruz Biotechnology) was added and incubated for 10 min at room
temperature before the addition of labeled oligonucleotide. Binding of
the antibody to NF-
B was indicated by a supershift in the
electrophoretic mobility shift assay. To further demonstrate specificity, excess unlabeled oligonucleotide was used as a specific competitor.
Statistical analysis. Unpaired Student's t-test was used to analyze differences between experimental groups. Statistical significance was accepted within 95% confidence limits.
| |
RESULTS |
|---|
|
|
|---|
Diminished uterine NF-
B p65 in pregnant
IL-1
/
mice.
Although immunostaining with anti-NF-
B p65 antibody revealed
immunoreactivity in uterine sections from both
IL-1
+/+ and
IL-1
/
mice, a
marked reduction of intracellular NF-
B protein was observed in
endometrial tissue from
IL-1
/
mice
compared with IL-1
+/+. As
depicted in Fig.
1A,
intense intracellular NF-
B staining (red) was detected in
endometrial tissue from IL-1
+/+
mice following LPS-induced pregnancy loss. Because the
tissue was taken 24 h after the intracervical LPS challenge, most of this immunoreactivity was observed in cytoplasm. In contrast, IL-1
/
mice
demonstrated significantly less intracellular NF-
B immunoreactivity in endometrial tissue (Fig. 1B). A
similar difference in NF-
B immunoreactivity was observed in
myometrium of IL-1
+/+ and
IL-1
/
mice;
however, this difference was not as dramatic as that observed in
endometrial tissue (data not shown).
|
+/+ and
IL-1
/
are not due
to unequal numbers of macrophages in endometrial tissue (data not shown).
Diminished NF-
B p65 protein in the uterus and spleen
of pregnant
IL-1
/
mice.
With Western immunoblotting, NF-
B p65 protein was detected in the
uterus of both pregnant and nonpregnant
IL-1
+/+ and
IL-1
/
mice. As
depicted in Fig.
2A,
endocervical LPS injection was associated with an increase in uterine
NF-
B levels in both IL-1
+/+
and IL-1
/
pregnant mice. Nevertheless, compared with
IL-1
+/+ pregnant mice, pregnant
IL-1
/
animals,
both saline and LPS-injected, exhibited lower uterine content of
NF-
B p65 protein. Densitometric analysis revealed that 24 h after
LPS administration, NF-
B uterine levels in
IL-1
/
were
50-60% of those in
IL-1
+/+ mice.
|
B protein content were observed in spleen
homogenates of LPS-challenged
IL-1
+/+ and
IL-1
/
mice (Fig.
2B). Twenty-four hours after LPS
injection, NF-
B levels in spleen of
IL-1
+/+ mice were approximately
twofold higher than those of
IL-1
/
mice.
Electrophoretic mobility shift assay demonstrates the different
activity of NF-
B p65-containing complex in pregnant
uterus.
The binding of NF-
B p50 and p65 protein-containing complex was
detected in the uterus of both
IL-1
+/+ and
IL-1
/
pregnant
mice. As depicted in Fig. 3, compared with
IL-1
+/+ mice, NF-
B
p50-containing complexes in
IL-1
/
animals
were reduced by 10%, whereas the level of p65-containing complexes
appeared to be reduced by 60%.
|
IL-1
deficiency is associated with diminished
uterine cytokine production in response to LPS administration in
pregnant mice.
Compared with saline, administration of LPS to
IL-1
+/+ and
IL-1
/
pregnant
mice induced an increase in uterine content of MIP-1
and TNF-
(Fig. 4, A
and B); however, in pregnant
IL-1
/
mice, the
LPS-induced elevation of uterine TNF-
and MIP-1
was two- to
threefold less (P < 0.05) than that
in IL-1
+/+ mice. A similar
finding was observed for interferon-
; however, a 1.6-fold difference
did not reach statistical significance.
|
Spleens of pregnant
IL-1
/
mice
exhibit diminished cytokine production in response to LPS
administration in vivo.
Twenty-four hours after in vivo LPS administration, the content of
MIP-1
in spleens of pregnant
IL-1
+/+ mice was 40% lower
than the corresponding level in nonpregnant IL-1
+/+ mice (Fig.
5A).
However, in IL-1
/
mice MIP-1
levels were 80% less (P < 0.01) than that in pregnant IL-1
+/+ mice (Fig.
5A). Spleen TNF-
also was 50%
lower in pregnant
IL-1
/
mice
compared with pregnant IL-1
+/+
mice; however, this difference was not statistically significant (P = 0.1).
|
and TNF-
were measured in
culture medium 24 h after in vitro LPS stimulation of splenocytes obtained from untreated pregnant mice. Although the differences did not
reach statistical significance, a trend toward lower MIP-1
(Fig.
5B) and TNF-
levels was observed
in IL-1
/
spleen
cells compared with IL-1
+/+
splenocytes. No differences in cytokine production were observed when
spleen cells from nonpregnant
IL-1
+/+ and
IL-1
/
mice were
stimulated in vitro with LPS.
Progesterone treatment of splenocyte cultures from nonpregnant
IL-1
/
mice
reveals diminished cytokine production in response to LPS
administration in vitro.
Concentrations of MIP-1
and TNF-
were measured in culture medium
from splenocytes obtained from untreated, nonpregnant
IL-1
+/+ and
IL-1
/
mice.
Splenocytes were initially incubated for 4 h in the presence of
progesterone; LPS was then added. Preincubation with progesterone suppressed production of MIP-1
and TNF-
, measured 24 h after the
in vitro addition of LPS, in a dose-dependent manner (Fig. 6). Progesterone pretreatment at 200 ng/ml
reduced LPS-induced MIP-1
and TNF-
production in splenocytes from
IL-1
+/+ by 10 and 30%,
respectively, whereas in
IL-1
/
mice this
cytokine production was additionally reduced by 25% compared with
IL-1
+/+ mice.
|
| |
DISCUSSION |
|---|
|
|
|---|
We observed that pregnancy in
IL-1
/
mice is
associated with decreased LPS-induced uterine and splenic cytokines
compared with similarly challenged pregnant wild-type mice. With the
sole exception of leptin (15), there is no difference in the response
to LPS between
IL-1
/
and
IL-1
+/+ nonpregnant mice (18).
Thus the present findings were unexpected. The most likely explanation
for the decrease in LPS-inducible cytokines in pregnant
IL-1
/
mice is a
reduction in the amount of the p65 component of NF-
B. In pregnant
IL-1
/
mice, we
observed a marked decrease of p65 immunostaining in the endometrium. A
40-50% reduction in uterine p65 protein levels was also detected
by Western blotting in
IL-1
/
compared
with IL-1
+/+ pregnant mice.
These findings were confirmed by gel super-shift electromobility assay
of nuclear extracts from pregnant uteri. These changes corresponded to
decreased LPS-induced NF-
B-mediated uterine cytokine production in
IL-1
/
pregnant
mice. Thus by four separate methods, we conclude that IL-1
participates in the regulation of steady-state levels of NF-
B p65 in
murine endometrium and splenocytes.
Specific staining of endometrial tissue for macrophages using the
anti-F4/80 antibody demonstrated that endometrial macrophages are not
the major source of NF-
B in uterus. In normal pregnancy, uterine
levels of IL-1 increase as parturition approaches (12). In the absence
of pregnancy and thus in the absence of high levels of progesterone and
estrogens, differences in NF-
B protein levels between
IL-1
+/+ and
IL-1
/
mice were
not detected. During pregnancy, progesterone, known to suppress the
function of NF-
B (24, 44, 45, 47), is elevated. As pregnancy
progresses, there is increased production of IL-1
and likely a
concomitant increase in NF-
B synthesis. This IL-1
-orchestrated
increase in p65 overcomes the suppression of NF-
B activity by
progesterone. However, in the absence of IL-1
, this apparently does
not take place and thus a relative lower level of p65 was observed.
This finding implicates a role for IL-1
in the steady-state level of
p65 that was not observed in nonpregnant
IL-1
/
mice.
The transcription factor NF-
B regulates gene expression of a variety
of proteins induced during immune and inflammatory responses, including
several cytokines. Typically, NF-
B is characterized as a heterodimer
comprised of a 50-kDa (p50) and a 65-kDa (p65) subunit (10). In
addition to the heterodimer p50-p65, homodimers also recognize the
common DNA sequence binding motif. Although p50-p50 or p65-p65
homodimers both have been previously proposed to be involved in gene
expression by selective activation of genes, p65-containing complexes
are most frequently reported as initiating transcription factors (4,
35). In contrast to p65 homo- or heterodimers, the p50 homodimer is
considered to function as an inhibitory complex displacing the p50-p65
or p50-c-rel heterodimers from the NF-
B binding sites (8). The
reduction in LPS-induced cytokines and slightly reduced p50 binding in
the gel-shift assay suggest that a partial reduction in p50 may also
take place in IL-1
/
mice. This
is consistent with the report that the p65 subunit increases activation
of p50 subunit gene expression (46). NF-
B is activated by many
stimuli, including oxidants, bacterial products, viruses, inflammatory
cytokines, and immune stimuli (2). This activation involves the
multistep process based on the interaction of dimerized DNA-binding
subunits with the inhibitor of NF-
B (I-
B) proteins in the cytosol
with subsequent phosphorylation of I-
B and followed by nuclear
translocation of NF-
B (29, 40). However, in the present study, we
show that reduced LPS-induced cytokines are associated with relatively
lower amounts of p65.
The gene encoding for NF-
B is constitutively autoregulated by
NF-
B (10). Also, in most situations, NF-
B activity is regulated posttranscriptionally (2). Nevertheless, in different cells NF-
B-mediated response to various stimuli may be either dependent or
independent of novel protein synthesis. For example, in HL-60 cells,
phorbol ester-induced NF-
B nuclear translocation was found to be
dependent on de novo protein synthesis, whereas in murine 70Z/3 cells,
NF-
B activation in response to phorbol esters was protein synthesis
independent (22). Recently, several messengers, including Ets proteins,
were reported to bind the NF-
B p50 promoter. It was suggested that
these proteins were responsible for a fine tuning of NF-
B gene
expression in different cell types (26).
The present study demonstrates a possible involvement of IL-1
in the
regulation of steady-state levels of NF-
B/p65 in murine endometrium.
IL-1
is a potent activator of NF-
B translocation, inducing its
activity rapidly via a protein synthesis-independent mechanism (6).
IL-1
and IL-1
also have been reported to increase steady-state
levels of NF-
B2 (p52) transcript and protein (25). The difference in
endometrial NF-
B protein levels and in NF-
B-mediated cytokine
production revealed during pregnancy may be due to rising levels of
progesterone during gestation. This hypothesis was supported by the
greater reduction of in vitro LPS-induced MIP-1
and TNF-
production in progesterone-treated
IL-1
/
splenocytes. There were no differences in LPS-induced cytokine responses in splenocytes cultured from nonpregnant
IL-1
+/+ or
IL-1
/
mice,
whereas a 4-h exposure to progesterone at a concentration similar to
levels circulating in pregnancy (3) decreased LPS-induced cytokine
production in
IL-1
/
mice 25%
greater than in IL-1
+/+ mice.
Progesterone has been reported to modulate macrophage-dependent immune
responses (32). In murine macrophages, progesterone inhibits inducible
nitric oxide synthase gene expression and nitric oxide production (31).
It also has been reported that progesterone modulation of macrophage
responses, and particularly of LPS-induced nitrite release by murine
peritoneal macrophages, is a receptor-mediated process (39).
Progesterone suppresses TNF-
mRNA and protein synthesis in
LPS-activated murine macrophages and human peripheral blood mononuclear
cells (28, 33). These effects may be explained by
1) the negative interaction between
the NF-
B p65 subunit and the progesterone receptor (24, 47) and/or
2) the progesterone-induced increase
of I-
B
protein translocated to the nucleus (33). We presume that
the relative reduction of NF-
B protein associated with IL-1
deficiency determines the greater sensitivity of LPS-challenged IL-1
/
mice to the
anti-inflammatory effects of progesterone. In splenocytes from
IL-1
+/+ mice, blocking IL-1
with IL-1Ra reduced LPS-induced TNF-
and MIP-1
production by
10-15%; however, in the presence of progesterone, this reduction
is greatly enhanced (unpublished observation). Associated with this reduction, we observed a reduction in p65 by
Western blotting after 24-h incubation of IL-1Ra plus progesterone (unpublished observation).
Although NF-
B has been well described as an important regulator of
proinflammatory cytokine production (5, 42, 44, 48, 49), the observed
changes in NF-
B protein associated with IL-1
deficiency might be
considered as only a partial contribution to the complex mechanism of
cytokine regulation in vivo. However, along with the potential effects
of other transcription factors or recently described involvement of
IL-1
in the regulation of I-
B kinase activity (13), the influence
of IL-1
on NF-
B protein levels may lend an additional insight
into the regulation of the cytokine network in vivo.
Perspectives
Constitutive NF-
B gene expression and protein levels are present in
nearly all types of cells. In the present understanding, the regulation
of NF-
B-mediated events, including proinflammatory cytokine
production, takes place posttranscriptionally when NF-
B complexes
are released from I-
B and translocate to the nucleus. Changes in
steady-state NF-
B protein levels could be considered another
regulatory mechanism that remained unknown. Thus the role of IL-1
in
the modulation of NF-
B protein levels, demonstrated by reduced level
of NF-
B p65 in
IL-1
/
mice and
decreased proinflammatory cytokine response to LPS in pregnancy, offers
an alternative regulatory mechanism. The importance of some
proinflammatory cytokines may not be apparent until "pressured" under specific circumstances. In the case of pregnancy, a thoroughly physiological circumstance, "pressuring" constitutive NF-
B
expression takes place but is revealed by IL-1
deficiency. At issue
is that "nature" would not leave NF-
B synthesis, such an
important regulator of the inflammatory response during pregnancy, to
just one gene product, either progesterone or IL-1
. Hence
understanding the regulation of NF-
B is one of uncovering the
components of this regulation. That during pregnancy inflammatory
diseases are suppressed is well established. Now we are seeing part of
this mechanism at the molecular level.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. H. Zhang for providing IL-1
-deficient mice and Dr.
F. Gamboni-Robertson for assistance.
| |
FOOTNOTES |
|---|
This work was supported by the National Institutes of Health Grants AI-15614 to C. A. Dinarello and AI-2532359 to L. L. Reznikov and Colorado Cancer Center Grant CA-46943.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: C. A. Dinarello, Univ. of Colorado Health Sciences Center, Div. of Infectious Diseases, Campus Box B-168, 4200 East Ninth Ave., BRB 401, Denver, CO 80262 (E-mail: leonid.reznikov{at}uchsc.edu).
Received 17 May 1999; accepted in final form 10 August 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Auron, P. E.,
and
A. C. Webb.
Interleukin-1: a gene expression system regulated at multiple levels.
Eur. Cytokine Netw.
5:
573-592,
1994[Web of Science][Medline].
2.
Barnes, P. J.
Nuclear factor-kappa B.
Int. J. Biochem. Cell Biol.
29:
867-870,
1997[Web of Science][Medline].
3.
Beamer, W. G.,
M. C. Wilson,
and
E. H. Leiter.
Endocrinology.
In: Normative Biology, Immunology, and Husbandry, edited by H. L. Foster,
J. D. Small,
and J. G. Fox. New York: Academic, 1983, p. 215.
4.
Beg, A. A.,
W. C. Sha,
R. T. Bronson,
S. Ghosh,
and
D. Baltimore.
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B.
Nature
376:
167-170,
1995[Medline].
5.
Bondeson, J.,
K. A. Browne,
F. M. Brennan,
B. M. Foxwell,
and
M. Feldmann.
Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent.
J. Immunol.
162:
2939-2945,
1999
6.
Bonizzi, G.,
E. Dejardin,
B. Piret,
J. Piette,
M. P. Merville,
and
V. Bours.
Interleukin-1 beta induces nuclear factor kappa B in epithelial cells independently of the production of reactive oxygen intermediates.
Eur. J. Biochem.
242:
544-549,
1996[Web of Science][Medline].
7.
Brandon, J. M.
Distribution of macrophages in the mouse uterus from one day to three months after parturition, as defined by the immunohistochemical localization of the macrophage-restricted antigens F4/80 and macrosialin.
Anat. Rec.
240:
233-242,
1994[Medline].
8.
Brigelius-Flohe, R.,
B. Bilgin,
S. Eickemeier,
R. Hipskind,
M. Singh,
M. Szamel,
and
K. Resch.
The NF kappa B heterodimer/homodimer balance and IL-1-stimulated IL-2 production in murine T lymphocytes.
Biofactors
5:
169-174,
1995-1996[Web of Science][Medline].
9.
Cogswell, J. P.,
M. M. Godlevski,
G. B. Wisely,
W. C. Clay,
L. M. Leesnitzer,
J. P. Ways,
and
J. G. Gray.
NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site.
J. Immunol.
153:
712-723,
1994[Abstract].
10.
Cogswell, P. C.,
R. I. Scheinman,
and
A. S. J. Baldwin.
Promoter of the human NF-kappa B p50/p105 gene. Regulation by NF-kappa B.
J. Immunol.
150:
2794-2804,
1993[Abstract].
11.
Coligan, J. E.,
A. M. Kruisbeek,
D. H. Margulies,
E. M. Shevach,
and
W. Strober.
In vitro assays for mouse lymphocyte function.
In: Current Protocols in Immunology. New York: Wiley, 1992.
12.
De, M.,
T. H. Sanford,
and
G. W. Wood.
Detection of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in the uterus during the second half of pregnancy in the mouse.
Endocrinology
131:
14-20,
1992
13.
Delhase, M.,
M. Hayakawa,
Y. Chen,
and
M. Karin.
Positive and negative regulation of I-
B kinase activity through IKK
subunit phosphorylation.
Science
284:
309-313,
1999
14.
Dinarello, C. A.
Biological basis for interleukin-1 in disease.
Blood
87:
2095-2147,
1996
15.
Faggioni, R.,
G. Fantuzzi,
J. Fuller,
C. A. Dinarello,
K. R. Feingold,
and
C. Grunfeld.
IL-1
mediates leptin induction during inflammation.
Am. J. Physiol. Regulatory Integrative Comp. Physiol.
274:
R204-R208,
1998
16.
Fantuzzi, G.,
and
C. A. Dinarello.
The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice.
J. Leukoc. Biol.
59:
489-493,
1996[Abstract].
17.
Fantuzzi, G.,
G. Ku,
M. W. Harding,
D. L. Livingston,
J. D. Sipe,
K. Kuida,
R. A. Flavell,
and
C. A. Dinarello.
Response to local inflammation of IL-1
converting enzyme-deficient mice.
J. Immunol.
158:
1818-1824,
1997[Abstract].
18.
Fantuzzi, G.,
H. Zheng,
R. Faggioni,
F. Benigni,
P. Ghezzi,
J. D. Sipe,
A. R. Shaw,
and
C. A. Dinarello.
Effect of endotoxin in IL-1
-deficient mice.
J. Immunol.
157:
291-296,
1996[Abstract].
19.
Fenton, M. J.,
B. D. Clark,
K. L. Collins,
A. C. Webb,
A. Rich,
and
P. E. Auron.
Transcriptional regulation of the human prointerleukin 1 beta gene.
J. Immunol.
138:
3972-3979,
1987[Abstract].
20.
Fenton, M. J.,
M. W. Vermeulen,
B. D. Clark,
A. C. Webb,
and
P. E. Auron.
Human pro-IL-1 beta gene expression in monocytic cells is regulated by two distinct pathways.
J. Immunol.
140:
2267-2273,
1988[Abstract].
21.
Hiscott, J.,
J. Marois,
J. Garoufalis,
M. D'Addario,
A. Roulston,
I. Kwan,
N. Pepin,
J. Lacoste,
H. Nguyen,
G. Bensi,
and
M. Fenton.
Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop.
Mol. Cell. Biol.
13:
6231-6240,
1993
22.
Hohmann, H. P.,
R. Remy,
C. Scheidereit,
and
A. P. van Loon.
Maintenance of NF-kappa B activity is dependent on protein synthesis and the continuous presence of external stimuli.
Mol. Cell. Biol.
11:
259-266,
1991
23.
Ikejima, T.,
S. Ikusawa,
P. Ghezzi,
J. W. M. van der Meer,
and
C. A. Dinarello.
IL-1 induces TNF in human PBMC in vitro and a circulating TNF-like activity in rabbits.
J. Infect. Dis.
162:
215-221,
1990[Web of Science][Medline].
24.
Kalkhoven, E.,
S. Wissink,
P. T. van der Saag,
and
B. van der Burg.
Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor.
J. Biol. Chem.
271:
6217-6224,
1996
25.
Kurzrock, R.,
Z. Estrov,
S. Ku,
M. Leonard,
and
M. Talpaz.
Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines.
J. Lab. Clin. Med.
131:
261-268,
1998[Web of Science][Medline].
26.
Lambert, P. F.,
M. J. Ludford-Menting,
N. J. Deacon,
I. Kola,
and
R. R. Doherty.
The NF-
B1 promoter is controlled by proteins of the Ets family.
Mol. Biol. Cell
8:
313-323,
1997[Abstract].
27.
Lebedeva, T. V.,
and
A. K. Singh.
Constitutive activity of the murine IL-1 beta promoter is regulated by a transcriptional repressor.
Biochim. Biophys. Acta
1353:
32-38,
1997[Medline].
28.
Loy, R. A.,
J. A. Loukides,
and
M. L. Polan.
Ovarian steroids modulate human monocyte tumor necrosis factor alpha messenger ribonucleic acid levels in cultured human peripheral monocytes.
Fertil. Steril.
58:
733-739,
1992[Web of Science][Medline].
29.
Matthews, J. R.,
and
R. T. Hay.
Regulation of the DNA binding activity of NF-kappa B.
Int. J. Biochem. Cell Biol.
9:
865-879,
1995.
30.
McManus, C. M.,
C. F. Brosnan,
and
J. W. Berman.
Cytokine induction of MIP-1 alpha and MIP-1 beta in human fetal microglia.
J. Immunol.
160:
1449-1455,
1998
31.
Miller, L.,
E. W. Alley,
W. J. Murphy,
S. W. Russell,
and
J. S. Hunt.
Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages.
J. Leukoc. Biol.
59:
442-450,
1996[Abstract].
32.
Miller, L.,
and
J. S. Hunt.
Sex steroid hormones and macrophage function.
Life Sci.
59:
1-14,
1996[Web of Science][Medline].
33.
Miller, L.,
and
J. S. Hunt.
Regulation of TNF-alpha production in activated mouse macrophages by progesterone.
J. Immunol.
160:
5098-5104,
1998
34.
Muhl, H.,
and
C. A. Dinarello.
Macrophage inflammatory protein-1 alpha production in lipopolysaccharide-stimulated human adherent blood mononuclear cells is inhibited by the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine.
J. Immunol.
159:
5063-5069,
1997[Abstract].
35.
Narayanan, R.,
K. A. Higgins,
J. R. Perez,
T. A. Coleman,
and
C. A. Rosen.
Evidence for differential functions of the p50 and p65 subunits of NF-kappa B with a cell adhesion model.
Mol. Cell. Biol.
13:
3802-3810,
1993
36.
Nishiyama, T.,
K. Mitsuyama,
A. Toyonaga,
E. Sasaki,
and
K. Tanikawa.
Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease.
Digestion
55:
368-373,
1994[Web of Science][Medline].
37.
Reznikov, L. L.,
G. Fantuzzi,
C. H. Selzman,
B. D. Shames,
H. A. Barton,
H. Bell,
J. A. McGregor,
and
C. A. Dinarello.
Utilization of endoscopic inoculation in a mouse model of intrauterine infection-induced preterm birth: role of interleukin-1
.
Biol. Reprod.
60:
1231-1238,
1999
38.
Robson, R. L.,
J. Westwick,
and
Z. Brown.
Interleukin-1-induced IL-8 and IL-6 gene expression and production in human mesangial cells is differentially regulated by cAMP.
Kidney Int.
48:
1767-1777,
1995[Web of Science][Medline].
39.
Savita, S.,
and
U. Rai.
Sex steroid hormones modulate the activation of murine peritoneal macrophages: receptor-mediated modulation.
Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol.
119:
199-204,
1998[Medline].
40.
Schmitz, M. L.,
and
P. A. Baeuerle.
Multi-step activation of NF-kappa B/Rel transcription factors.
Immunobiology
193:
116-127,
1995[Web of Science][Medline].
41.
Schreiber, E.,
P. Matthias,
M. M. Muller,
and
W. Schaffner.
Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.
Nucleic Acids Res.
17:
6419,
1989
42.
Shakhov, A. N.,
M. A. Collart,
P. Vassalli,
S. A. Nedospasov,
and
C. V. Jongeneel.
Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages.
J. Exp. Med.
171:
35-47,
1990
43.
Shalaby, M. R.,
A. Waage,
L. Aarden,
and
T. Espevik.
Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo.
Clin. Immunol. Immunopathol.
53:
488-498,
1989[Web of Science][Medline].
44.
Stein, B.,
and
M. X. Yang.
Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta.
Mol. Cell. Biol.
15:
4971-4979,
1995[Abstract].
45.
Szekeres-Bartho, J.,
and
T. G. Wegmann.
A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance.
J. Reprod. Immunol.
31:
81-95,
1996[Web of Science][Medline].
46.
Ueberla, K. L. Y.,
E. Chung,
and
W. A. Haseltine.
The NF-kappa B p65 promoter.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
6:
227-230,
1993.
47.
Van der Burg, B.,
and
P. T. van der Saag.
Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs.
Mol. Hum. Reprod.
2:
433-438,
1996
48.
Xia, Y.,
M. E. Pauza,
L. Feng,
and
D. Lo.
RelB regulation of chemokine expression modulates local inflammation.
Am. J. Pathol.
151:
375-387,
1997[Abstract].
49.
Yao, J.,
N. Mackman,
T. S. Edgington,
and
S. T. Fan.
Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors.
J. Biol. Chem.
272:
17795-17801,
1997
50.
Zheng, H.,
D. Fletcher,
W. Kozak,
M. Jiang,
K. Hofmann,
C. C. Conn,
D. Siszynski,
C. Grabiec,
M. A. Trumbauer,
A. R. Shaw,
M. J. Kostura,
K. Stevens,
H. Rosen,
R. J. North,
H. Y. Chen,
M. J. Tocci,
M. J. Kluger,
and
L. H. T. van der Ploeg.
Resistance to fever induction and impaired acute-phase response in interleukin-1b deficient mice.
Immunity
3:
9-19,
1995[Web of Science][Medline].
This article has been cited by other articles:
![]() |
J. P. Granger Maternal and fetal adaptations during pregnancy: lessons in regulatory and integrative physiology Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2002; 283(6): R1289 - R1292. [Full Text] [PDF] |
||||
![]() |
M. A. Zimmerman, C. H. Selzman, L. L. Reznikov, S. A. Miller, C. D. Raeburn, J. Emmick, X. Meng, and A. H. Harken Lack of TNF-alpha attenuates intimal hyperplasia after mouse carotid artery injury Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R505 - R512. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Heimbach, L. L. Reznikov, C. M. Calkins, T. N. Robinson, C. A. Dinarello, A. H. Harken, and X. Meng TNF receptor I is required for induction of macrophage heat shock protein 70 Am J Physiol Cell Physiol, July 1, 2001; 281(1): C241 - C247. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |